Driving reinvestment in R&D for antibiotics and advocating their responsible use

DRIVE-AB Outputs: Slide Sets

Stephan Brussles Pres ThumbnailDRIVE-AB – Driving Re-Investment in R&D and Responsible Antibiotic Use

Delivered by Stephan Harbarth, University of Geneva
COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET General Assembly, 14-16 March 2017, Brussels, Belgium

 

 

 

 

ursule-imed-pres-thumbnailEcology and environmental drivers of antibiotic resistance

Delivered by Ursula Theuretzbacher, Center for Anti-Infective Agents
International Meeting on Emerging Diseases and Surveillance, held on 4-7 November 2016, Vienna, Austria.

 

 

 

ardal-slide-titleDRIVE-AB – Driving re-investment in R&D and responsible antibiotic use

Delivered by Work Package 2 Co-lead Christine Årdal, Norwegian Institute of Public Health
Organisation for Economic Co-operation and Development (OECD) Expert Group on the Economics of Prevention meeting, 11 October, 2016

 

 

 

 

 

Conference ThumbnailSlide sets from the DRIVE-AB Conference: Stimulating innovation, sustainable use and global access to antibiotics

Slide sets from presentations given at the DRIVE-AB Conference, held on 2 June, 2016, in Amsterdam.

 

 

 

 

 

 

 

Inge Pres ECCMID Training session April 2016 image

DRIVE-AB Train-the-Trainer Event: Defining and implementing responsible Antibiotic use, Part I

Delivered by Inge Gyssens, Jeroen Schouten and Marlies Hulscher
DRIVE-AB Train-the-Trainer event, Amsterdam, 2016

 

 

 

training event celine presentation coverDRIVE-AB Train-the-Trainer Event: Defining and implementing responsible antibiotic use, Part II

Delivered by Céline Pulcini. Benedikt Huttner and Vera Vlahovic-Palcevski
DRIVE-AB Train-the-Trainer event, Amsterdam, 2016

 

 

 

 

ECCMID presentation quality indicators 2016Quality indicators of antibiotic use in the inpatient setting: a global consensus procedure

Delivered by DRIVE-AB Work Package 1A participant Annelie Monnier, Radboud University Medical Center at the European Congress on Clinical Microbiology and Infection, Amsterdam, 2016

 

 

 

Stephan Harbarth Geneva Pharma Forum presWhy should we care about multi-resistant bacteria? Clinical impact and public health implications

Delivered by Prof Stephan Harbarth, Université de Genève / Infection Control Program
Geneva Pharma Forum, Geneva, 2015

 

 

 

John Rex IFPMA ImageEnabling drug discovery and development to address the crisis of antibacterial resistance: New tools, new pathways and remaining challenges

Delivered by Dr John Rex, AstraZeneca
Geneva Pharma Forum, Geneva, 2015

 

 

 

Back to DRIVE-AB Outputs